L

Larimar Therapeutics
D

LRMR

4.21000
USD
-0.06
(-1.41%)
مغلق
حجم التداول
46,880
الربح لكل سهم
-1
العائد الربحي
-
P/E
-3
حجم السوق
360,335,550
الأخبار المقالات

العنوان: Larimar Therapeutics

القطاع: Healthcare
الصناعة: Biotechnology
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.